Prevalence of Metabolic Syndrome and of Cardiovascular Risk Factors

Manta Andrei 1 , Maștaleru Alexandra 1 , Oancea Andra 1 , Anghel Razvan Constantin 1 , Roca Mihai 1 , Leon-Constantin Maria Magdalena 1 , and Mitu Florin 1
  • 1 University of Medicine and Pharmacy “Grigore T Popa”,, Faculty of Medicine, Department Medical I


Obesity, a component of the metabolic syndrome, is a rising public health problem, continuously increasing in the European countries. The therapeutic success of the patient with metabolic syndrome requires a multidisciplinary approach to lifestyle changes, weight loss, continuous and dynamic dietary improvement, sedentary reduction, normalization of blood pressure, glycemia and lipid parameters. We performed a retrospective study that was conducted in the Clinical Rehabilitation Hospital in Iasi, with 4627 patients that were admitted in the Cardiovascular Rehabilitation Clinic from January 2011 to December 2015 with the diagnosis of metabolic syndrome according to WHO definition (Group 1) or with other comorbidities (Group 2). In the first group were included 1064 patients diagnosed with metabolic syndrome. This group has predominantly smoking female patients. Also, in group 1 were diagnosed more patients with left ventricular hypertrophy and coronary heart disease compared to group 2. Most of the patients with inflammatory syndrome were included in the group without metabolic syndrome (group 2). The results of our study confirm that metabolic syndrome is a cluster of abnormalities whose evolution determines the development of coronary heart disease. All this would advocate for treating metabolic syndrome as the primary method of preventing cardiovascular disease.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Heinsch R. Avizul Comitetului Economic și Social European privind consecin ele îmbătrânirii popula iei asupra sistemelor de sănătate și de protec ie socială (aviz exploratoriu). Jurnalul Oficial al Uniunii Europene. 2011/C 44/02, p 10-16.

  • 2. Diabetes Canada Clinical Practice Guidelines Expert Committee, Punthakee Z, Goldenberg R, Katz P. Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome. Can J Diabetes. 2018;42 Suppl 1:S10-S15.

  • 3. O’Neill S, O’Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015;16(1):1-12.

  • 4. Wang H, Sun Y, Yi X, Zhang L. Evaluation of the Framingham risk score and pooled cohort risk equation for prediction of cardiovascular risk in low resource areas: Insights from Asian rural population. Int J Cardiol. 2018;265:237.

  • 5. Fonseca FAH, Izar MCO. Prevalence of Metabolic Syndrome and Framingham Risk Score in Vegetarian and Omnivorous Apparently Healthy Men. Arq Bras Cardiol. 2018;110(5):438-439.

  • 6. Vanavanan S, Srisawasdi P, Rochanawutanon M, Kumproa N, Kruthkul K, Kroll MH. Performance of body mass index and percentage of body fat in predicting cardiometabolic risk factors in Thai adults. Diabetes Metab Syndr Obes. 2018;11:241-253.

  • 7. Schorr M, Dichtel LE, Gerweck AV et al. Sex differences in body composition and association with cardiometabolic risk. Biol Sex Differ. 2018;9(1):28.

  • 8. Cerezo C, Segura J, Praga M, Ruilope LM. Guidelines updates in the treatment of obesity or metabolic syndrome and hypertension. Curr Hypertens Rep. 2013;15(3):196-203.

  • 9. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-52.

  • 10. Ren Z, Zhao A, Wang Y et al. Association between Dietary Inflammatory Index, C-Reactive Protein and Metabolic Syndrome: A Cross-Sectional Study. Nutrients. 2018;10(7). pii: E831.

  • 11. Stafeev IS, Menshikov MY, Tsokolaeva ZI, Shestakova MV, Parfyonova YV. Molecular Mechanisms of Latent Inflammation in Metabolic Syndrome. Possible Role of Sirtuins and Peroxisome Proliferator-Activated Receptor Type γ. Biochemistry (Mosc). 2015;80(10):1217-26.

  • 12. Kang JH, Song YM. Association between cotinine-verified smoking status and metabolic syndrome: analyses of Korean National Health and Nutrition Examination Surveys 2008-2010. Metab Syndr Relat Disord. 2015;13(3):140-8.

  • 13. Song YM, Chang WD, Hsu HY, Chen MD. A short-term smoking cessation may increase the risk of developing metabolic syndrome. Diabetes Metab Syndr. 2015;9(2):135-7.

  • 14. Riahi SM, Moamer S, Namdari M, Mokhayeri Y, Pourhoseingholi MA, Hashemi-Nazari SS. Patterns of clustering of the metabolic syndrome components and its association with coronary heart disease in the Multi-Ethnic Study of Atherosclerosis (MESA): A latent class analysis. Int J Cardiol. 2018. pii: S0167-5273(17)37027-4.

  • 15. Lan Y, Mai Z, Zhou S et al. Prevalence of metabolic syndrome in China: An up-dated cross-sectional study. PLoS One. 2018;13(4):e0196012.


Journal + Issues